New Xtandi data bolster case for pre-chemo use
This article was originally published in Scrip
Astellas and Medivation reported a 10-month progression-free survival benefit for Xtandi (enzalutamide) versus Casodex (bicalutamide) in a Phase II clinical trial designed to satisfy requests for a head-to-head comparison of the androgen receptor inhibitors in metastatic castrate-resistant prostate cancer (mCRPC).
You may also be interested in...
Full Circle: David Hung Looks Forward To Axovant's Alzheimer's Data, Reflects On Medivation
As the CEO of Axovant, David Hung is back where he started with Medivation – working on a drug for Alzheimer's disease.
Medivation Rejects Sanofi's Latest Bid, But Enters Confidential Negotiations
After two months of public, hostile back-and-forth, Sanofi agreed to confidentially discuss a potential acquisition of Medivation, putting the French pharma on equal footing with the biotech company's other suitors.
Building On Successes During Turbulent Times, SR One Closes $600m Fund II
SR One will keep investing in a mix of new companies, early-stage firms and later opportunities with its second fund, raised even as biotech continues to endure challenging financial times.